The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Julian Adams, Ph.D., of Infinity Pharmaceuticals Named Corporate Chair for The Leukemia & Lymphoma Society's Light the Night Walk

<p class='bwalignc'> <i>Urges Local Businesses Take the First Step to Help Beat Cancer</i> </p>

Monday, September 16, 2013

Julian Adams, Ph.D., of Infinity Pharmaceuticals Named Corporate Chair for The Leukemia & Lymphoma Society's Light the Night Walk

16:00 EDT Monday, September 16, 2013

NATICK, Mass. (Business Wire) -- The Massachusetts chapter of The Leukemia & Lymphoma Society (LLS) named Julian Adams, Ph.D., of Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) as corporate chair of its 2014 Light The Night® Walk, LLS's annual fundraising event for cancer research and patient services. Dr. Adams serves as president, research and development, at Infinity and is responsible for the full spectrum of the company's drug discovery, preclinical and clinical development strategy and regulatory affairs activities.

LLS holds walks each fall in approximately 200 communities across the United States and Canada. Participants at the walks carry illuminated balloons – white for survivors, red for supporters, and gold to remember those who have died – to honor and commemorate lives touched by blood cancer.

“Forming Light The Night Walk teams is a great way to build team spirit among employees, raise awareness about the need for more blood cancer therapies and recognize those who continue to be affected by these diseases,” said Dr. Adams. “These same objectives – and our desire to continue our support of LLS – led us to recently launch Infinity Pharmaceuticals' “Sparks of Inspiration” campaign. I am honored to serve as the chair of the 2014 Light The Night Walk and look forward to helping more local businesses and corporations get their employees involved.”

Prior to joining Infinity in 2003, Dr. Adams served as senior vice president, drug discovery and development at Millennium Pharmaceuticals. In this capacity, he held global responsibility for multiple drug discovery programs, including the successful discovery and development of Velcade® (bortezomib), a proteasome inhibitor for two different blood cancers: multiple myeloma and relapsed mantle cell lymphoma. He previously held senior management positions with organizations such as LeukoSite, ProScript, Inc. and Boehringer Ingelheim, where he successfully discovered the drug Viramune® (nevirapine) for HIV. Dr. Adams' awards include the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, the 2012 C. Chester Stock Award Lectureship from Memorial Sloan-Kettering Cancer Center, and the 2001 Ribbon of Hope Award for Velcade® from the International Myeloma Foundation.

The funds raised through corporate and individual contributions during the Light The Night® Walk help to find cures and better therapies for leukemia, lymphoma, Hodgkin disease and myeloma. Donations also provide information, education and support for patients and their families.

“Light The Night Walk gives hope to patients and their families and lets them know they are not alone in their battle against cancer,” said Sharon Klein, executive director of the Massachusetts chapter of the LLS.

To find out more about forming a team or participating in a Light The Night walk, contact the Massachusetts Chapter at 508-810-1342, or www.lightthenight.org

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.

About Infinity's “Sparks of Inspiration” Campaign
Infinity Pharmaceuticals, Inc. is an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases. Throughout September, Infinity is observing National Blood Cancer Awareness Month, joining patients, healthcare providers and patient organizations in raising public awareness of blood cancers and the need for continued research for novel treatment options. In support of patients and their loved ones, Infinity is launching the Sparks of Inspiration campaign. Infinity encourages the submission of stories along with photos and illustrations honoring friends, family members or loved ones affected by blood cancer. For each submission received, Infinity will make a $10 donation to the Leukemia & Lymphoma Society, up to a total of $5,000. Submissions can be made through Infinity's website www.infi.com. Submissions will be accepted through September 30, 2013.

Leukemia & Lymphoma Society
Ahlea Isabella, 508-810-1311
Ahlea.Isabella@lls.org

Products
  • Globe Unlimited

    Digital all access pass across devices. subscribe

  • The Globe and Mail Newspaper

    Newspaper delivered to your doorstep. subscribe

  • Globe2Go

    The digital replica of our newspaper. subscribe

  • Globe eBooks

    A collection of articles by the Globe. subscribe

See all Globe Products

Advertise with us

GlobeLink.ca

Your number one partner for reaching Canada's Influential Achievers. learn more

Digital Business Solutions
Our Company
Customer Service
Globe Recognition
Mobile Apps
NEWS APP
INVESTING APP
Other Sections